Aptose Biosciences Inc. (NASDAQ:APTO) Sees Significant Growth in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 2,090,000 shares, an increase of 1,012.9% from the December 15th total of 187,800 shares. Approximately 3.7% of the company’s shares are sold short. Based on an average daily volume of 6,360,000 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on APTO shares. HC Wainwright reiterated a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a report on Friday, January 10th. StockNews.com started coverage on Aptose Biosciences in a research report on Wednesday, January 8th. They issued a “hold” rating for the company.

Aptose Biosciences Trading Up 0.1 %

Shares of APTO traded up $0.00 on Wednesday, reaching $0.20. 297,946 shares of the company’s stock were exchanged, compared to its average volume of 1,077,562. The business has a 50 day moving average price of $0.24 and a two-hundred day moving average price of $0.39. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.42. The stock has a market capitalization of $12.23 million, a P/E ratio of -0.07 and a beta of 0.87.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.